Filip Janku (@FilipJankuMD) header
Filip Janku (@FilipJankuMD) profile picture

Medical Oncologist, Cancer Researcher, Drug Developer, ex-@MDAndersonNews, Chief Medical Officer @MonteRosaTx. Views are mine.

Boston, MA
Joined August 2017
Photo by Filip Janku (@FilipJankuMD)Photo by Filip Janku (@FilipJankuMD)Photo by Filip Janku (@FilipJankuMD)Photo by Filip Janku (@FilipJankuMD)Photo by Filip Janku (@FilipJankuMD)Photo by Filip Janku (@FilipJankuMD)Photo by Filip Janku (@FilipJankuMD)Photo by Filip Janku (@FilipJankuMD)Photo by Filip Janku (@FilipJankuMD)
It feels like #Bluesky time 😁
2
393
Just in case anyone is interested in joining 🦋. I have been pleasantly surprised. Lot of #MedTwitter crowd migrated there.
3
638
ICYMI: Our team was on the ground for this week’s 7th #TPD and Induced Proximity Summit. View our presentations to learn more about Monte Rosa’s work on CDK2 and Cyclin E1 #moleculargluedegraders, as well as our programs in GSPT1 and VAV1. bit.ly/3ChLkrJ
2
1
5
1,023
Attending the 7th #TPD and Induced Proximity Summit? Nina Ilic-Widlund, Director of Oncology Biology, shares how we’re accelerating the rational discovery and design of #moleculargluedegraders, including CDK2 and Cyclin E1 #MGDs. Join us to learn more! bit.ly/40nWpS9
5
12
840
Interested in Monte Rosa’s molecular glue degraders for #oncology and #autoimmune diseases? Chief Medical Officer @FilipJankuMD presents on how we’re taking #MGDs from the bench to the clinic at the 7th #TPD and Induced Proximity Summit. bit.ly/40nWpS9
1
5
559
I’m happy to share that Novartis and @MonteRosaTx have announced an exclusive global development and commercialization license agreement to advance molecular glue degraders. ir.monterosatx.com/news-rele…
5
1
57
4,447
We believe VAV1 molecular glue degraders such as MRT-6160 have the potential for a differentiated therapeutic profile in T-cell, T/B-cell, and Th17-mediated indications. It’s our hope this agreement moves us a step closer to bringing MRT-6160 to patients worldwide.
Today we announced a global license agreement with @Novartis to advance VAV1-directed MGDs. This agreement is expected to accelerate clinical development of MRT-6160 and explore its therapeutic potential across multiple indications. Learn more: bit.ly/3YDsioB
2
13
2,162
Deeply humbled to receive the 2024 Pulitzer Prize for my @washingtonpost columns written from prison. I dedicate it to all journalists imprisoned in Russia — and the monetary part will go the 30 October Foundation that helps the families of Russian political prisoners.
50
309
32
1,364
562,815
The piece focuses on how companies including Monte Rosa are pushing the boundaries of the druggable target space with molecular glue degraders for GSPT1, VAV1, and other novel targets.
2
3
435
Thanks to Asher Mullard and @NatRevDrugDisc for the great article and interview with our CEO Markus Warmuth and our CSO Sharon Townson. nature.com/articles/d41573-0…
1
1
1
7
576
Focusing on undruggable targets isn’t just an intellectual pursuit but it’s also incredibly important for patients. It’s our great hope that by striking out in new directions, we can provide much-needed new therapeutic options for patients. I am very proud of the team @MonteRosaTx for leading the way in this pursuit of new #MolecularGlueDegraders.
Replying to @MonteRosaTx
Sharon Townson, our Chief Scientific Officer, and John Castle, Chief Data and Information Officer, comment on the key takeaways. Read the publication here: bit.ly/3YmFEWk Special thanks to first authors Georg Petzold and Pablo Gainza!
3
552
Sharon Townson, our Chief Scientific Officer, and John Castle, Chief Data and Information Officer, comment on the key takeaways. Read the publication here: bit.ly/3YmFEWk Special thanks to first authors Georg Petzold and Pablo Gainza!
2
1
6
1,003
At Monte Rosa, we have taken the bold and differentiating approach of focusing the development of our #moleculargluedegraders (MGDs) on previously undruggable targets. Today we published a paper demonstrating how we do it in BioRxiv.org.
1
3
19
1,258
🦄UPDATE on qualifier registration for the 129th Boston Marathon presented by @BankofAmerica🦄 24,069 qualifiers who ran 6:51 or faster than their qualifying standard have been accepted into April’s race!💙💛 Email notices have begun being issued. 🔗 bstnmar.org/25BMAcceptances
26
48
77
279
99,540
Welcome to @zrh_airport 🥲🥲🥲. Lucky me that I am not connecting
2
2
167
Khin Naing Foundation USA will be volunteering at @HoustonFoodBank in memory of Dr. Jing Gong @JingGong14 on 10/13/24. Join us at knfoundation-usa.com/dr-jing… as we honor Dr. Gong's legacy by lending a helping hand to those in need. #KhinNaingFoundationUSA
1
12
13
2,278
VAV1 as a putative therapeutic target in autoimmune and chronic inflammatory diseases dlvr.it/TBg66r
3
1
17
7,311
We’re changing the game for #ColorectalCancer screening w/ the FDA approval of Shield, our blood test for people age 45+ at average risk. With Shield, we aim to get more people tested & catch more cancers early, when they’re most treatable. Read more: bit.ly/3WnfKzi
2
52
7
41
11,804
VAV1 as a putative therapeutic target in autoimmune and chronic inflammatory diseases dlvr.it/TB4WV7 #immunology
1
14
1
54
6,490